Crispr Therapeutics AG (NASDAQ:CRSP) major shareholder Corp /De/ Celgene sold 87,991 shares of the firm’s stock in a transaction on Friday, December 1st. The shares were sold at an average price of $19.10, for a total value of $1,680,628.10. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Large shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.

Corp /De/ Celgene also recently made the following trade(s):

  • On Wednesday, November 29th, Corp /De/ Celgene sold 4,263 shares of Crispr Therapeutics stock. The shares were sold at an average price of $19.25, for a total value of $82,062.75.
  • On Monday, November 27th, Corp /De/ Celgene sold 27,990 shares of Crispr Therapeutics stock. The shares were sold at an average price of $19.75, for a total value of $552,802.50.
  • On Friday, November 24th, Corp /De/ Celgene sold 26,010 shares of Crispr Therapeutics stock. The shares were sold at an average price of $20.00, for a total value of $520,200.00.
  • On Wednesday, November 22nd, Corp /De/ Celgene sold 256,000 shares of Crispr Therapeutics stock. The shares were sold at an average price of $19.76, for a total value of $5,058,560.00.
  • On Monday, November 20th, Corp /De/ Celgene sold 158,718 shares of Crispr Therapeutics stock. The shares were sold at an average price of $19.02, for a total value of $3,018,816.36.
  • On Friday, November 17th, Corp /De/ Celgene sold 51,282 shares of Crispr Therapeutics stock. The shares were sold at an average price of $18.44, for a total value of $945,640.08.
  • On Wednesday, November 15th, Corp /De/ Celgene sold 15,000 shares of Crispr Therapeutics stock. The shares were sold at an average price of $17.67, for a total value of $265,050.00.
  • On Monday, November 13th, Corp /De/ Celgene sold 65,093 shares of Crispr Therapeutics stock. The shares were sold at an average price of $17.76, for a total value of $1,156,051.68.
  • On Friday, November 10th, Corp /De/ Celgene sold 10,000 shares of Crispr Therapeutics stock. The shares were sold at an average price of $17.28, for a total value of $172,800.00.
  • On Wednesday, November 8th, Corp /De/ Celgene sold 16,875 shares of Crispr Therapeutics stock. The shares were sold at an average price of $18.06, for a total value of $304,762.50.

Shares of Crispr Therapeutics AG (CRSP) traded up $0.01 during mid-day trading on Thursday, reaching $18.53. The company had a trading volume of 197,500 shares, compared to its average volume of 142,711. Crispr Therapeutics AG has a 1 year low of $11.63 and a 1 year high of $25.00.

Crispr Therapeutics (NASDAQ:CRSP) last announced its quarterly earnings data on Wednesday, November 8th. The company reported ($0.62) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.60) by ($0.02). The firm had revenue of $2.39 million during the quarter, compared to analyst estimates of $3.61 million. Crispr Therapeutics had a negative return on equity of 38.42% and a negative net margin of 466.58%. Crispr Therapeutics’s revenue for the quarter was up 54.2% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($2.77) earnings per share. analysts anticipate that Crispr Therapeutics AG will post -2.46 EPS for the current year.

A number of analysts recently commented on the company. BidaskClub lowered Crispr Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, December 2nd. Chardan Capital reiterated a “buy” rating on shares of Crispr Therapeutics in a research report on Monday, August 14th. Cann reiterated a “hold” rating on shares of Crispr Therapeutics in a research report on Thursday, November 9th. SunTrust Banks reiterated a “hold” rating and issued a $16.00 price objective on shares of Crispr Therapeutics in a research report on Friday, November 10th. Finally, Barclays reiterated a “buy” rating and issued a $29.00 price objective on shares of Crispr Therapeutics in a research report on Friday, September 8th. Four equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average target price of $22.38.

Institutional investors have recently bought and sold shares of the company. Hershey Trust Co. acquired a new position in shares of Crispr Therapeutics during the 3rd quarter worth about $768,000. Credit Suisse AG acquired a new position in shares of Crispr Therapeutics during the 1st quarter worth about $1,742,000. Tiff Advisory Services Inc. acquired a new position in shares of Crispr Therapeutics during the 3rd quarter worth about $505,000. Adams Street Partners LLC acquired a new position in shares of Crispr Therapeutics during the 3rd quarter worth about $1,019,000. Finally, Capital Investment Advisory Services LLC acquired a new position in shares of Crispr Therapeutics during the 3rd quarter worth about $193,000. Institutional investors own 24.55% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Crispr Therapeutics AG (CRSP) Major Shareholder Sells $1,680,628.10 in Stock” was originally published by American Banking News and is the sole property of of American Banking News. If you are accessing this report on another domain, it was copied illegally and republished in violation of United States and international copyright and trademark laws. The correct version of this report can be read at https://www.americanbankingnews.com/2017/12/07/crispr-therapeutics-ag-crsp-major-shareholder-sells-1680628-10-in-stock.html.

About Crispr Therapeutics

Crispr Therapeutics AG is a Switzerland-based gene-editing company. The Company focuses on the development of transformative gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform. CRISPR/Cas9 can be programmed to cut, edit and correct disease-associated deoxyribonucleic acid (DNA) in a patient’s cell.

Insider Buying and Selling by Quarter for Crispr Therapeutics (NASDAQ:CRSP)

Receive News & Ratings for Crispr Therapeutics AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics AG and related companies with MarketBeat.com's FREE daily email newsletter.